Article Writer-   Minakshi  Kumari, MSc. Biotechnology , RCA, Maharana Pratap University of Agriculture and Technology ,Udaipur, Rajsthan(India)

Ahistorical development has been made in the field of Medical Sciences, at the Oregon Health and Science University Casey Eye Institute, where Gene-editing pioneer Editas Medicine and Allergan announced that a patient had been dosed with the first-ever CRISPR-Cas9 based in-vivo therapy, for Leber’s Congenital Amaurosis(LCA). LCA is an eye disorder that greatly affects the retina.

Previously CRISPR-Cas9 was tested ex-vivo for editing T-Cells, but this is the first time where CRISPR-Cas9 system is used inside the human beings itself i.e. In-vivo.

This extraordinary effort by the Researchers will further push the development of CRISPR-Cas9 technology for direct correction of Genetic lesions.

Journal Reference:

The clinical cutting edge. Nat Biotechnol 38, 767 (2020). https://doi.org/10.1038/s41587-020-0612-2